Stocks · News reference

Spruce Biosciences Says It Completed Two Pre-BLA Meetings With FDA Supporting Q4 2026 BLA Submission For Tralesinidase Alfa In Sanfilippo Syndrome Type B; FDA Found CMC Comparability Strategies Reasonable

Aug 24, 2026, 12:02 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 12:07 PMBenzinga Newsdesk
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and TrAnsform Confirmatory
Read original at benzinga
SPRB
BenzingaAug 17, 2026, 1:22 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104
Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.
Read original at benzinga
SPRB
BenzingaAug 13, 2026, 1:58 PMBenzinga Newsdesk
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.
Read original at benzinga
SPRB